Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (242)	1/27/1998 9:23:00 PM
From: Rick Strange	Read Replies (1) \| Respond to of 507

David, What you say sounds reasonable and the same thought crossed my own mind. Maybe REUTERS finally screwed up a story? In any event, it does seem to add creditability to the multicomponent argument don't you think?

To: David Bogdanoff who wrote (242)	1/29/1998 9:59:00 AM
From: Don W Stone	Respond to of 507

David: You are right in your thinking . My understanding is that pertactin is a problem. This mutation could bring that point home. All the competitive vaccines to include the old whole cell include the pertactin component. CERTIVA IS MONOCOMPONENT. If the mutation continues to show up CERTIVA may be the only vaccine that will handle it. Based on what i have been told all pertussis vaccines in the future will be absent of pertactin. I think we we'll be hearing alot more about the pertactin problem in the future.